Skip to main content
Clinical Trials/NCT04413578
NCT04413578
Completed
Phase 4

Assessing the Feasibility of Continuous Glucose Monitoring in Reimagine Primary Care Clinics

Intermountain Health Care, Inc.4 sites in 1 country101 target enrollmentDecember 1, 2018

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Diabetes Mellitus, Type 2
Sponsor
Intermountain Health Care, Inc.
Enrollment
101
Locations
4
Primary Endpoint
HbA1c Variation
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

To assess the impact of continuous glucose monitoring versus standard of care (e.g. a finger-prick protocol using a glucometer) on clinical outcomes, healthcare utilization, and cost in patients with type I or II diabetes treated within the Reimagine Primary Care clinics.

Detailed Description

This is a parallel randomized controlled trial. Eligible patients who consent will be randomized to one of two groups: (1) the intervention group who will be given a Dexcom G6 for CGM, or (2) the control group who will follow their current standard finger-prick protocol via a provided Contour Next ONE glucometer. The CGM group must download the Dexcom G6 and Clarity mobile apps for data capture, whereas the standard of care group will use the Contour Next mobile app for their respective readings. The Dexcom G6 captures real-time, dynamic glucose data every five minutes. Devices used in this study are FDA approved and commercially available.

Registry
clinicaltrials.gov
Start Date
December 1, 2018
End Date
December 31, 2019
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Type 1 or type 2 diabetes mellitus with a HbA1c ≥6.5%
  • Patients that are currently managing their glucose levels for diabetes with a glucose meter (or will be prescribed one by their healthcare provider)
  • Patients that are treated within the four Reimagine Primary Care clinics (Cottonwood Family Medicine, Cottonwood Senior, Avenues Internal Medicine, and Holladay Internal Medicine). • Patients 18-80 years of age

Exclusion Criteria

  • Patients that are not managing their glucose levels for diabetes (and not advised to use a glucose monitor by their physician)
  • Patients that are not treated within the four Reimagine Primary Care clinics
  • Patients less than 18 years of age, and 81 years of age and older
  • Patients with a diagnosis of dementia
  • If the patient is currently using a Continuous Glucose Monitor
  • Patients with previous hospitalization for hypoglycemia within the last 18 months
  • No access to a mobile phone to download the Dexcom or Contour Next applications
  • Patients who are pregnant or planning to become pregnant over the course of their six-month participation

Outcomes

Primary Outcomes

HbA1c Variation

Time Frame: 6 months

Coefficient of variation in HbA1c levels before, during and end of study completion.

HbA1c Range

Time Frame: 6 months

Variation of range in HbA1c levels before, during and end of study completion.

Secondary Outcomes

  • Current Diabetes Standards(6 months)
  • Behavioral Changes(6 months)
  • Hypoglycemic Events(6 months)
  • Healthcare Utilization(6 months)
  • Glycemic Variability(6 months)
  • Emergency Room Visits(6 months)
  • Healthcare Cost(6 months)

Study Sites (4)

Loading locations...

Similar Trials